Triple Artemisinin-based Combination Therapy for Delaying Drug Resistance Development - a Randomized Clinical Trial

Inclusion Criteria

• •Patients presenting at the health facility with suspected acute uncomplicated malaria will be screened for eligibility.
• •Age from 6 - 120 months
• •Weight ≥ 5 kg
• •Body temperature ≥37.5°C or history of fever in the last 24 hours
• •Microscopy confirmed P. falciparum mono-infection
• •Parasitemia level of 1000-200000/μL
• •Ability to swallow oral medication
• •Ability and willingness to abide by the study protocol and the stipulated follow-up visits
• •A written proxy informed consent from a parent/guardian